Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
8-Methoxy-4-[(2-isopropylphenyl)amino]-3-quinolinecarboxylate ethyl ester (
AHR
-9294) inhibited acid secretion stimulated by histamine, pentagastrin or carbachol in rats, and by histamine or feeding in dogs.
AHR
-9294 was about half as potent as omeprazole and exhibited a shorter duration of action. Based on its inhibition of acid secretion induced by different secretagogues and its lack of effect on histamine-stimulated
adenylate cyclase
activity,
AHR
-9294 does not appear to operate at the histamine receptor or
adenylate cyclase
. Rather, studies on enriched oxyntic microsomal preparations showed
AHR
-9294 to be an effective inhibitor of the H+ pump enzyme, H,K-ATPase, suggesting this might be the site of antisecretory activity. Kinetic studies revealed that inhibition of both K(+)-activated ATPase and p-nitrophenylphosphatase by
AHR
-9294 was purely competitive with K+ and its congeners, indicating that
AHR
-9294 and its analogs belong to the class of compounds known as "K+)-site" inhibitors. On the other hand, inhibition by
AHR
-9294 was noncompetitive with both ATP and p-nitrophenylphosphatase on their respective rates of hydrolysis (i.e., both Vmax and the apparent Km were reduced, but Vmax/Km was unchanged). Studies on partial reactions of the H,K-ATPase showed that the rate of ATP/ADP exchange was unaffected by
AHR
-9294 and the steady-state level of phosphoenzyme was only partially reduced (thus ATP/enzyme interaction was not affected); however, the rate of K(+)-catalyzed dephosphorylation of phosphoenzyme was markedly decreased.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:AHR-9294: a novel inhibitor of H,K-ATPase antagonizes gastric HCl secretion in vivo. 131 65
Prostaglandin E(2) (PGE(2)) has been shown to negatively affect pancreatic beta-cell function, and its inducible synthesis is mediated in part by cycloxygenase-2 (COX-2). Regulation of basal and inducible COX-2 gene expression in pancreatic beta-cells is not fully understood. In this report, we used pancreatic beta-cells (RINm5F) to explore the molecular mechanisms regulating COX-2 promoter activity. Through deletion analysis of a -907/+70-bp 5' upstream region of the mouse COX-2 gene, we identified an inhibition domain (-804/-371) and an activation domain (-371/+70). The highest promoter activity was seen when the promoter was reduced to -371 bp. Several cis-acting elements were selected for site-directed mutations in the activation domain. We identified three sites that were essential for basal COX-2 promoter activity: 1) CCAAT/enhancer-binding protein (C/EBP), 2)
aryl hydrocarbon receptor
(
AhR
), and 3) cAMP response element-binding protein (CREB). Single mutation of each individual site inhibited 70-80% of basal COX-2 promoter activity. Double mutation of the
AhR
and CREB-binding sites showed synergy in repressing COX-2 promoter activity as did mutation of all three sites. We demonstrated that the transcription factors from RINm5F nuclear extracts specifically bound to oligonucleotides containing C/EBP,
AhR
, or CREB consensus sites. Forskolin, an activator of
adenyl cyclase
, increased COX-2 promoter activity via the CREB site. COX-2 promoter activity was also increased by 2,3,7,8-tetrachlorodibenzo-p-dioxin, an
AhR
activator, through the
AhR
site. Both forskolin and 2,3,7,8-tetrachlorodibenzo-p-dioxin increased COX-2 mRNA in a dose-dependent manner. We consider these three transcriptional regulators of COX-2 expression to be potential targets for the prevention of beta-cell damage mediated by PGE(2).
...
PMID:Transcriptional regulation of cyclooxygenase-2 gene in pancreatic beta-cells. 1521 29
We employed DNA microarray to identify unique hepatic gene expression patterns associated with subchronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and other halogenated aromatic hydrocarbons (HAHs). Female Harlan Sprague-Dawley rats were exposed for 13 weeks to toxicologically equivalent doses of four different HAHs based on the toxic equivalency factor of each chemical: TCDD (100 ng/kg/day), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF; 200 ng/kg/day), 3,3',4,4',5-pentachlorobiphenyl (PCB126; 1,000 ng/kg/day), or 2,2',4,4',5,5'-hexachlorobiphenyl (PCB153; 1,000 microg/kg/day). Global gene expression profiles for each exposure, which account for 8,799 gene probe sets contained on Affymetrix RGU34A GeneChips, were compared by principal components analysis. The
aryl hydrocarbon receptor
(
AhR
) ligands TCDD, PeCDF, and PCB126 produced very similar global gene expression profiles that were unique from the nonAhR ligand PCB153, underscoring the extensive impact of
AhR
activation and/or the resulting hepatic injury on global gene expression in female rat liver. Many genes were co-expressed during the 13-week TCDD, PeCDF, or PCB126 exposures, including classical
AhR
-regulated genes and some genes not previously characterized as being
AhR
regulated, such as carcinoembryonic-cell adhesion molecule 4 (C-CAM4) and
adenylate cyclase
-associated protein 2 (CAP2). Real-time reverse-transcriptase polymerase chain reaction confirmed the increased expression of these genes in TCDD-, PeCDF-, and PCB126-exposed rats as well as the up- or down-regulation of several other novel dioxin-responsive genes. In summary, DNA microarray successfully identified dioxin-responsive genes expressed after exposure to
AhR
ligands (TCDD, PeCDF, PCB126) but not after exposure to the non-
AhR
ligand PCB153. Together, these findings may help to elucidate some of the fundamental features of dioxin toxicity and may further clarify the biologic role of the
AhR
signaling pathway.
...
PMID:Subchronic exposure to TCDD, PeCDF, PCB126, and PCB153: effect on hepatic gene expression. 1559 15
This study characterizes the muscarinic cholinergic receptors associated with the inhibition of
adenylate cyclase
on N18TG2 neuroblastoma cell membranes. Agonists could be divided into two classes: oxotremorine, acetylcholine, carbachol and arecoline exerted the most efficacious and potent inhibition, while McN-A343, bethanechol and
AHR
-602 were partial agonists. Both quinuclidinyl benzilate and atropine maximally antagonized the inhibitory effect of McN-A343, carbachol and oxotremorine. Pirenzepine was almost as potent as atropine in reversing the inhibitory effect of McN-A343, but was 300 times less potent than atropine or quinuclidinyl benzilate in antagonizing the effects of either carbachol or oxotremorine. Gallamine was ineffective as an antagonist at concentrations up to 1 mM. These results suggest that the receptors that modulate this inhibition are of the M(2) type, since they were activated by carbachol, acetylcholine and oxotremorine, but much less by McN-A343 and
AHR
-602 (both M(1) selective agonists). The full agonists were blocked by atropine and quinuclidinyl benzilate but not by low concentrations of pirenzepine (M(1) selective antagonist).
...
PMID:Muscarinic pharmacology of the inhibition of adenylate cyclase in N18TG2 neuroblastoma cells. 2050 Nov 73